Who is eligible for clinical trial NCT03528694?

Participants must meet protocol criteria for Non-muscle-invasive Bladder Cancer. Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT03528694 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-07-03

Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer (NCT03528694)

A Phase III Randomized, Open-Label, Multi-Center, Global Study of Durvalumab and Bacillus Calmette-Guerin (BCG) Administered as Combination Therapy Versus BCG Alone in High-Risk, BCG Naïve Non-Muscle Invasive Bladder Cancer Patients

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: AstraZeneca

🩺 Plain-English Summary (8th-Grade Level)

This is a randomized, open-label, multi-center, global, phase III study to determine the efficacy and safety of Durvalumab + BCG combination therapy in the treatment of patients with non-muscle-invasive bladder cancer

Who can join: Review the eligibility criteria below.

Location: Research Site — Auchenflower

Age range: 18 Years to 130 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (120 Sites)

Showing the first 25 of 120 sites.

Research Site — Auchenflower,
Research Site — Box Hill,
Research Site — Brisbane,
Research Site — Kogarah,
Research Site — Orange,
Research Site — Parkville,
Research Site — Westmead,
Research Site — Wollongong,
Research Site — Graz,
Research Site — Innsbruck,
Research Site — Linz,
Research Site — Salzburg,
Research Site — Vienna,
Research Site — Brussels,
Research Site — Ghent,
Research Site — Leuven,
Research Site — Roeselare,
Research Site — Kingston, Ontario
Research Site — Toronto, Ontario
Research Site — Chicoutimi, Quebec
Research Site — Montreal, Quebec
Research Site — Québec, Quebec
Research Site — Amiens,
Research Site — Angers,
Research Site — Bordeaux,

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Non-muscle-invasive Bladder Cancer

Intravesical BCG vs GEMDOCE in NMIBC — Birmingham, Alabama
A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer — Little Rock, Arkansas
Replacing Invasive Cystoscopy With Urine Testing for Non-muscle Invasive Bladder Cancer Surveillance — West Haven, Connecticut
Artificial Intelligence Prediction Tool in Non-muscle Invasive Bladder Cancer (NMIBC) — Dallas, Texas
A Phase I Intravesical PPM Therapy for NMIBC — Boston, Massachusetts

Explore by condition: All Non-muscle-invasive Bladder Cancer clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Review the official NIH record below to find the coordinating site.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗